+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
ID07021794

Evaluating Sipavibart Monoclonal Antibody Treatment for Long COVID Symptoms A Randomized, Placebo-Controlled Phase II Study

Led by Nancy Klimas · Updated on 2026-09-29

100

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and potential effectiveness of Sipavibart, a targeted monoclonal antibody, for patients experiencing Long COVID symptoms. This phase II, randomized, placebo-controlled, and triple-blinded study focuses on individuals aged 18 to 70 who have persistent symptoms following acute COVID-19 infection. The study aims to understand if Sipavibart can help reduce inflammation and viral activation associated with Long COVID. Participants are randomly assigned to receive either a single 300 mg intramuscular dose of Sipavibart or a matching placebo injection. After this single treatment, they are followed for six months to monitor their symptoms and health status. At the end of this period, those still experiencing Long COVID symptoms may join an open-label extension phase where they can receive Sipavibart openly regardless of their initial group. During the study, participants will complete various assessments including patient-reported outcome measures at 12 and 24 weeks, and evaluations of fatigue, cognitive function, heart rate, blood pressure responses, symptom scores, and quality of life questionnaires. Safety is monitored through tracking treatment-related adverse events. The total involvement includes the initial treatment and six months of follow-up with detailed health evaluations.

CONDITIONS

Brief Title

SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

Research Team

N

Nancy Klimas, MD

A

Alejandro Montealegre, MSN, ARNP

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here